Clinical Trials in the UK / NCT04557449
Recruiting
Phase 1/2
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449 · tracked via the Priya Life Science UK tracker
Condition(s) studied
LiposarcomaProstate CancerAdvanced Breast CancerNSCLC (Non-small Cell Lung Cancer)Colorectal Cancer
Investigational drug(s) / intervention(s)
PF-07220060: CDK4 inhibitor
Letrozole: Endocrine Therapy
Fulvestrant: Endocrine Therapy
Midazolam: Benzodiazepine
Enzalutamide: Androgen Receptor inhibitor
Giredestrant: Endocrine Therapy
Tamoxifen: Endocrine Therapy
Study summary
This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy.
Part 1 includes dose escalation cohorts evaluating PF-07220060 as single agent or in combination with endocrine therapy or enzalutamide, as well as a food effect cohort and a DDI cohort.
Part 2 includes dose expansion cohorts evaluating PF-07220060 in combination with endocrine therapy or enzalutamide.
The Giredestrant Combination Cohort will evaluate PF-07220060 in combination with giredestrant.
In Part 1A, single escalating doses of PF-07220060 alone will be administered to determine the maximum tolerated dose (MTD) and select the recommended dose for expansion.
In Part 1B and Part 1C, PF-07220060 will be administered in combination with 1 of 2 endocrine therapies (letrozole and fulvestrant, respectively).
In Part 1D, food effect assessment of PF-07220060 at the RP2D dose level from Part 1A will be conducted.
In Part 1E, the effect of PF-07220060 on the PK of midazolam will be evaluated (DDI).
In Part 1F, escalating doses of PF-07220060 will be administered in combination with enzalutamide.
In Part 1G, PF-07220060 will be administered in combination with tamoxifen to determine the RDE.
Part 2A is an expansion cohort for PF-07220060 in combination with fulvestrant and will explore more than one dose of PF-07220060.
Part 2B and Part 2C are expansion cohorts for PF-07220060 in combination with letrozole and fulvestrant, respectively.
Part 2E is an expansion cohort to evaluate PF-07220060 Monotherapy versus PF-07220060 plus fulvestrant combination therapy.
Part 2F is an expansion cohort for PF-07220060 in combination with tamoxifen.
The Giredestrant Combination Cohort Group A will determine the tolerable dose of PF-07220060 in combination with giredestrant. In Group B, additional participants will be enrolled at the tolerable dose to further assess safety and PK.
The China and Japan monotherapy cohorts will evaluate safety, tolerability, and PK of PF-07220060 as single agent in Chinese and Japanese participants, respectively.
Eligibility
Inclusion Criteria
* Part 1: Breast Cancer (BC)
* Refractory Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) BC
* Part 1A/Part 1D/Part 1E also include: Refractory HR-positive/HER2-positive BC
* Part 1: Tumors other than BC (Part 1A/Part 1D/Part 1E): NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification according to local standard tests
* Part 1F: prostate cancer
* Part 1G: HR-positive/HER2-negative BC
* Part 2A, 2B, 2C, 2E, and 2F: HR-positive/HER2-negative BC
* Part 1D: metastatic castration resistant prostate cancer
* Giredestrant Combination Cohort: ER-positive/HER2-negative BC
* Prior systemic Treatment
* Part 1: HR-positive/HER2-negative BC
* At least 1 line of SOC, including CD4/6 inhibitor therapy for advanced or metastatic disease, or if CDK4/6 inhibitors are not considered appropriate in the opinion of the investigator
* HR-positive/HER2-positive BC (Parts 1A/1D/1E): at least 1 prior treatment of approved HER2 targeting therapy
* Tumors other than BC (Parts 1A/1D/1E/1F): tumor that is resistant to at least 2 lines of SOC for advanced or recurrent disease or for which no standard therapy is available
* Part 2A and 2E: at least 1 line of standard of care (including prior CDK4/6i) for advanced/metastatic disease; Prior chemo is allowed; Prior fulvestrant, mTOR and/or PI3K inhibitors are allowed
* Part 2B: no prior systemic anti-cancer therapies for advanced/metastatic BC
* Part 2C:
* Progressed during treatment or within 12 months of completion of adjuvant therapy with an aromatase inhibitor if postmenopausal, or tamoxifen if pre or perimenopausal, or
* Progressed while on or within 1 month after the endo the prior aromatase inhibitor therapy for advanced/metastatic BC if postmenopausal or prior endocrine treatment for advanced/metastatic BC if pre or perimenopausal
* One previous line of chemotherapy for advanced/metastatic disease is allowed in addition to endocrine therapy
* Part 1G and 2F: at least 2 lines of SOC for advanced or metastatic disease, including CDK4/6 inhibitor and endocrine therapy
* Giredestrant Combination Cohort: at least 1 (no more than 3) prior line(s) of SOC for advanced or metastatic disease, including CDK4/6 inhibitor and endocrine therapy
General Inclusion Criteria
* All participants must be refractory to or intolerant of existing therapies known to provide clinical benefit for their condition.
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
* Adequate renal, liver, and bone marrow function
Exclusion Criteria:
* Part 2B: prior neoadjuvant or adjuvant treatment with a non-steroidal aromatase inhibitor with disease recurrence while on or within 12 months of completing treatment. Prior treatment with any CDK4/6 inhibitor
* Part 2C: prior treatment with any CDK inhibitor, fulvestrant, everolimus, or any agent whose mechanism of action is to inhibit the PI3K-mTOR pathway
* Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases carcinomatous meningitis, or leptomeningeal disease
* Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ
* Major surgery or radiation within 4 weeks prior to study intervention
* Last anti-cancer treatment within 2 weeks prior to study intervention; Part 1G and 2F: tamoxifen treatment within 35 days of Day -4
* Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry
* Part 1G and 2F: history of or current pulmonary embolism or deep vein thrombosis
* Giredestrant Combination Cohort: history (within 6 months of screening) of or presence of idiopathic symptomatic bradycardia or resting heart rate \<50 bpm at screening
* Pregnant or breastfeeding female participant
* Active inflammatory gastrointestinal (GI) disease, known diverticular disease or previous gastric resection or lap band surgery including impairment of gastrointestinal function or GI disease
Primary outcome measure(s)
- Number of participants with dose limiting toxicities in the Dose Escalation or De-escalation Portion — At the end of Cycle 1 (each cycle is 28 days)
First cycle (28 days) dose limiting toxicities - Incidence of clinically significant AEs — Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
Adverse Events - Incidence of clinically significant laboratory assessments — Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
safety laboratory abnormalities - Incidence of clinically significant abnormal vital and ECG parameters — Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
vital signs and heart rate corrected QT interval - Maximal Plasma Concentration (Cmax) of PF-07220060 given with and without food — Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Part 1D) - Time to Maximum Plasma Concentration (Tmax) of PF-07220060 given with and without food — Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Part 1D) - Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Last Sampling Time Point (AUClast) of PF-07220060 given with and without food — Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Part 1D) - Maximal Plasma Concentration (Cmax) of Midazolam with and without PF-07220060 — Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Part 1E) - Time to Maximum Plasma Concentration (Tmax) of Midazolam with and without PF-07220060 — Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Part 1E) - Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Last Sampling Timepoint (AUClast) of Midazolam with and without PF-07220060 — Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Part 1E) - Steady State Maximal Concentration (Cmax,ss) of PF-07220060 — Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Giredestrant Combination Cohort) - Steady State Time to Maximum Plasma Concentration (Tmax,ss) of PF-07220060 — Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Giredestrant Combination Cohort) - Steady State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCτ,ss) of PF-07220060 — Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Giredestrant Combination Cohort) - Steady State Minimum Plasma Concentration (Cmin,ss) of PF-07220060 — Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments for PF-07220060 (Giredestrant Combination Cohort) - Steady State Maximal Concentration (Cmax,ss) of Giredestrant — Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments (Giredestrant Combination Cohort) - Steady State Time to Maximum Plasma Concentration (Tmax,ss) of Giredestrant — Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments (Giredestrant Combination Cohort) - Steady State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCτ,ss) of Giredestrant — Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments (Giredestrant Combination Cohort) - Steady State Minimum Plasma Concentration (Cmin,ss) of Giredestrant — Cycle 1 (each cycle is 28 days)
Pharmacokinetic (PK) assessments (Giredestrant Combination Cohort)
Trial sites (39)
| Facility | City | Region | Status |
|---|---|---|---|
| Ellison Institute | Los Angeles | California | Active Not Recruiting |
| Smilow Cancer Hospital - Yale New Haven Health | New Haven | Connecticut | Recruiting |
| Yale-New Haven Hospital-Yale Cancer Center | New Haven | Connecticut | Recruiting |
| Smilow Cancer Hospital Phase 1 Unit | New Haven | Connecticut | Recruiting |
| Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP | New Haven | Connecticut | Recruiting |
| Smilow Cancer Hospital - Trumbull | Trumbull | Connecticut | Recruiting |
| Brigham & Women's Hospital | Boston | Massachusetts | Active Not Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | Active Not Recruiting |
| Dana Farber Cancer Institute- Chestnut Hill | Newton | Massachusetts | Active Not Recruiting |
| START Midwest | Grand Rapids | Michigan | Recruiting |
| Sarah Cannon Research Institute - Pharmacy | Nashville | Tennessee | Recruiting |
| SCRI Oncology Partners | Nashville | Tennessee | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | Recruiting |
| The University of Texas, MD Anderson Cancer Center - West Houston | Houston | Texas | Recruiting |
| Hospital Británico de Buenos Aires | Ciudad Autónoma de Buenos Aires | Buenos Aires | Active Not Recruiting |
| Fundación Cenit Para La Investigación En Neurociencias | CABA | Ciudad Autã³noma de Buenos Aires | Active Not Recruiting |
| Fundación Respirar | Buenos Aires | Argentina | Active Not Recruiting |
| Clínica Universitaria Reina Fabiola | Córdoba | Argentina | Active Not Recruiting |
| Fundación CORI para la Investigación y Prevención del Cáncer | La Rioja | Argentina | Active Not Recruiting |
| Cancer Hospital Chinese Academy of Medical Science | Beijing | Beijing Municipality | Active Not Recruiting |
| Henan Cancer Hospital | Zhengzhou | Henan | Active Not Recruiting |
| Hubei Cancer Hospital | Wuhan | Hubei | Active Not Recruiting |
| The First Affiliated Hospital of Xi'an Jiaotong University | Xi’an | Shanxi | Active Not Recruiting |
| Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | Hangzhou | Zhejiang | Active Not Recruiting |
| Vseobecna fakultni nemocnice v Praze | Prague | Czechia | Active Not Recruiting |
| National Cancer Center Hospital East | Kashiwa | Chiba | Active Not Recruiting |
| COI Centro Oncologico Internacional S.A.P.I. de C.V. | Mexico City | Mexico City | Active Not Recruiting |
| Hospital MAC Periferico Sur | Mexico City | Mexico City | Active Not Recruiting |
| INCAN | Mexico City | Mexico City | Active Not Recruiting |
| Hospital Universitario "Dr. Jose Eleuterio Gonzalez" | Monterrey | Nuevo León | Active Not Recruiting |
| Hospital Reforma | Oaxaca City | Oaxaca | Active Not Recruiting |
| Oaxaca Site Management Organization | Oaxaca City | Mexico | Active Not Recruiting |
| Onkologicky ustav sv. Alzbety, s.r.o., Interna klinika VSZaSP a OUSA | Bratislava | Slovakia | Active Not Recruiting |
| Narodny onkologicky ustav | Bratislava | Slovakia | Active Not Recruiting |
| Fakultna nemocnica s poliklinikou Nove Zamky | Nové Zámky | Slovakia | Active Not Recruiting |
| Cancer Research UK Edinburgh Centre | Edinburgh | Edinburgh, CITY of | Active Not Recruiting |
| St Bartholomew's Hospital | London | London, CITY of | Active Not Recruiting |
| Sarah Cannon Research Institute UK | London | United Kingdom | Active Not Recruiting |
| The Christie Hospital NHS Foundation Trust | Manchester | United Kingdom | Active Not Recruiting |
On this site
📄 Xtandi (enzalutamide) drug profile →More Pfizer trials in the UK
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Active, not recruiting
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
Active, not recruiting
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Active, not recruiting
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
Active, not recruiting
Other trials for the same condition
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04557449 on ClinicalTrials.gov ↗ ← All trials in the UK